TissGeneSummary for ISLR2 |
Gene summary |
Basic gene information | Gene symbol | ISLR2 |
Gene name | immunoglobulin superfamily containing leucine-rich repeat 2 | |
Synonyms | LINX | |
Cytomap | UCSC genome browser: 15q24.1 | |
Type of gene | protein-coding | |
RefGenes | NM_001130136.1, NM_001130137.1,NM_001130138.1,NM_020851.2, | |
Description | immunoglobulin superfamily containing leucine-rich repeat protein 2leucine-rich repeat domain and immunoglobulin domain-containing axon extension protein | |
Modification date | 20141207 | |
dbXrefs | MIM : 614179 | |
HGNC : HGNC | ||
Ensembl : ENSG00000167178 | ||
HPRD : 13865 | ||
Vega : OTTHUMG00000137624 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_ISLR2 | |
BioGPS: 57611 | ||
Pathway | NCI Pathway Interaction Database: ISLR2 | |
KEGG: ISLR2 | ||
REACTOME: ISLR2 | ||
Pathway Commons: ISLR2 | ||
Context | iHOP: ISLR2 | |
ligand binding site mutation search in PubMed: ISLR2 | ||
UCL Cancer Institute: ISLR2 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | BrainTestis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | GBM,LGGTGCT | |
Reference showing the relevant tissue of ISLR2 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for ISLR2 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
BRCA | -0.392213485 | 0.96334441 | -1.355557895 | 1.11E-22 | 9.55E-22 |
KIRC | -2.65085369 | -1.182730079 | -1.468123611 | 4.06E-10 | 1.37E-09 |
KICH | -2.158677801 | -0.978133801 | -1.180544 | 0.00115 | 0.002463168 |
KIRP | -2.257624176 | -1.089830426 | -1.16779375 | 0.000188 | 0.000602137 |
Top |
TissGene-miRNA for ISLR2 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for ISLR2 |
TissGeneSNV for ISLR2 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.G48E | SKCM | 2 |
p.T55M | UCEC | 2 |
p.R5W | BLCA | 2 |
p.D644N | HNSC | 1 |
p.R153H | COAD | 1 |
p.P607S | LGG | 1 |
p.E497K | PAAD | 1 |
p.P659L | UCEC | 1 |
p.V45L | LUSC | 1 |
p.A60T | PAAD | 1 |
p.C614F | CESC | 1 |
p.R404W | PAAD | 1 |
p.Q275* | LUSC | 1 |
p.R648C | STAD | 1 |
p.G674E | SKCM | 1 |
p.R528C | UCEC | 1 |
p.E675G | THYM | 1 |
p.A490V | SKCM | 1 |
p.G69V | LUAD | 1 |
p.A163V | STAD | 1 |
p.W11G | HNSC | 1 |
p.A196V | LUSC | 1 |
p.A451T | HNSC | 1 |
p.P343H | LUAD | 1 |
p.R466G | LUAD | 1 |
p.R160H | BRCA | 1 |
p.R556C | HNSC | 1 |
p.G290R | HNSC | 1 |
p.A145V | STAD | 1 |
p.R626H | COAD | 1 |
p.P634R | LIHC | 1 |
p.S137Y | UCEC | 1 |
p.P147L | LUSC | 1 |
p.A172E | HNSC | 1 |
p.A60T | LGG | 1 |
p.P23L | PRAD | 1 |
p.P46S | LIHC | 1 |
p.T366M | LGG | 1 |
p.A681V | UCEC | 1 |
p.D168E | SKCM | 1 |
p.L558R | SKCM | 1 |
p.A252T | COAD | 1 |
p.G186D | SKCM | 1 |
p.Q673X | STAD | 1 |
p.Q313K | LUAD | 1 |
p.S137Y | READ | 1 |
p.R158W | LGG | 1 |
p.E675G | SARC | 1 |
p.S407R | LUAD | 1 |
p.A336P | LUSC | 1 |
p.R140W | COAD | 1 |
p.N470S | SKCM | 1 |
p.A212T | UCEC | 1 |
p.A336T | LIHC | 1 |
p.R5W | SKCM | 1 |
p.G278S | STAD | 1 |
p.D118N | UCEC | 1 |
p.P285S | UCEC | 1 |
p.V408I | PRAD | 1 |
p.G188S | STAD | 1 |
p.I628M | BLCA | 1 |
p.W195C | LUAD | 1 |
p.P534L | LIHC | 1 |
p.A172T | UCS | 1 |
p.Y467H | STAD | 1 |
p.G557C | LUAD | 1 |
p.A163V | HNSC | 1 |
p.R466Q | COAD | 1 |
p.Q691H | LUAD | 1 |
p.D678H | BLCA | 1 |
p.T55M | PRAD | 1 |
p.E41Q | BLCA | 1 |
p.A733T | PRAD | 1 |
p.A94T | UCEC | 1 |
p.P464S | LUSC | 1 |
p.R559W | COAD | 1 |
p.Q673* | STAD | 1 |
p.E586D | DLBC | 1 |
Top |
TissGeneCNV for ISLR2 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for ISLR2 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Chimerdb3.0 | ChiTaRs | NA | BM174926 | ISLR2-FRMPD4 | chr15:74427135 | chrX:12669899 |
Top |
TissGeneNet for ISLR2 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for ISLR2 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for ISLR2 |
TissGeneDrug for ISLR2 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for ISLR2 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |